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permits non-commercial use, distribution, and reproduction in any medium, provided the original author and source are credited.SUMMARYStem cell-derived cardiomyocytes represent unique tools for cell- and tissue-based regenerative therapies, drug discovery and safety, and
studies of fundamental heart-failure mechanisms. However, the degree to which stem cell-derived cardiomyocytes compare to mature
cardiomyocytes is often debated. We reasoned that physiological metrics of engineered cardiac tissues offer a means of comparison.
We built laminarmyocardium engineered from cardiomyocytes that were differentiated frommouse embryonic stem cell-derived cardiac
progenitors or harvested directly from neonatal mouse ventricles, and compared their anatomy and physiology in vitro. Tissues assem-
bled from progenitor-derivedmyocytes and neonatemyocytes demonstrated similar cytoskeletal architectures but different gap junction
organization and electromechanical properties. Progenitor-derived myocardium had significantly less contractile stress and slower
longitudinal conduction velocity than neonate-derived myocardium, indicating that the developmental state of the cardiomyocytes
affects the electromechanical function of the resultant engineered tissue. These data suggest a need to establish performance metrics
for future stem cell applications.INTRODUCTION
Cardiomyocytes can be derived from a variety of sources,
including embryonic stem cells (ESCs) (Anderson et al.,
2007; Braam et al., 2008; Caspi et al., 2007), induced plurip-
otent stem cells (iPSCs) (Gai et al., 2009; Zhang et al., 2009),
adult stem cells (Beltrami et al., 2003), and direct reprog-
ramming from fibroblasts (Ieda et al., 2010). Significant
efforts have been focused on the potential of these cells
to repair the heart following myocardial infarction (MI)
or to serve as in vitro models of disease. The standard
approach for assessing the differentiated state of these
derived myocytes has been to determine mRNA, miRNA,
and protein expression, as well as the electrophysiological
characteristics of myocytes via patch-clamp or calcium
imaging (Genead et al., 2010; Sirish et al., 2012). These
criteria are important, but they offer an incomplete assess-
ment of the myocyte’s physiology.
Cardiac tissue engineering may provide a tool for eval-
uating stem cell-derived myocytes. In previous studies,
primary harvest rodent (Alford et al., 2010; Baar et al.,
2005; Feinberg et al., 2007; Zimmermann et al., 2004)
and ESC-derived cardiac myocytes (Domian et al., 2009;
Guo et al., 2006; Stevens et al., 2009) were used as build-
ing substrates for engineered tissues whose functionStem Cell Rcould be rigorously evaluated. These studies demon-
strated that engineered tissues can be used as experi-
mental platforms to examine how stem cell-derived
cardiac myocytes spontaneously assemble the subcellular,
cellular, and supracellular architectures required to facili-
tate uniform spread of the action potential (AP) and
ordered contraction.
We reasoned that we could use engineered tissues as a
common test bed for cardiac myocytes from different sour-
ces to compare their inherent ability to build themselves
and collectively function. Previously, we identified specific
subsets of islet-1-expressing, ESC-derived cardiac progeni-
tors that are completely committed to the ventricular line-
age, and demonstrated that we could differentiate these
mouse progenitor cells into cardiac myocytes (progenitor-
derived myocytes) and use them to build laminar myocar-
dium (Domian et al., 2009). Here, we built upon that work
by conducting a detailed structural and functional analysis
of those engineered tissues. As a benchmark for compari-
son, we engineered similar tissues from neonatal mouse
ventricular myocytes. Our results suggest that engineered
myocardium from these different sources have distinct
functional differences that are critically important for the
assessment of such cells for scientific and therapeutic
applications.eports j Vol. 1 j 387–396 j November 19, 2013 j ª2013 The Authors 387
Figure 1. Structural Analysis of Engineered Myocardium from Neonate Myocytes and Progenitor-Derived Myocytes
(A) Neonate-derived myocardium had uniaxial cell alignment with sarcomere and Cx43 expression.
(B) At highermagnification (dashed yellowbox in A), the sarcomerica-actinin revealed Z disks with lateral registration spanning across cells.
(C) CX43 was localized to the cell-cell border between adjacent myocytes, suggesting electrical coupling.
(D) Intensity profile of Z-disk staining along a myofibril (yellow line in B) shows normal spacing of 1.99 ± 0.24 mm.
(E) Cytoskeletal orientation (actin filaments) in the neonate myocytes was uniaxially aligned in the direction of the underlying
FN-patterned substrate.
(F) Progenitor-derived myocardium also had uniaxial cell alignment with sarcomere and CX43 expression.
(G) At higher magnification (dashed yellow box in F), the sarcomeric a-actinin revealed Z disks with distinct sarcomeres, but decreased
lateral registration as compared with neonate myocytes.
(H) CX43 was localized to the cell-cell border between myocytes, but at decreased frequency as compared with neonate myocytes,
suggesting decreased electrical coupling.
(I) Intensity profile of Z-disk staining along a myofibril (yellow line in G) shows normal spacing of 2.01 ± 0.19 mm.
(J) Cytoskeletal orientation (actin filaments) in progenitor-derived myocytes was uniaxially aligned in the direction of the underlying
FN-patterned substrate.
(K) The thickness of the engineered myocardium was statistically different for the neonate myocytes on the brick pattern versus the
neonate myocytes on the line pattern and the progenitor-derived myocytes (ANOVA with Holm-Sidak pairwise comparison, *p < 0.025).
(L) The number of myocytes that stained positive for sarcomeric a-actinin was statistically equivalent between the progenitor- and
neonate-derived myocardia (ANOVA, p = 0.871).
(legend continued on next page)
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Progenitor-Derived versus Neonatal MyocardiumRESULTS
Structural Analysis of Engineered Myocardium
We reasoned that we could use soft lithography and
muscular thin films (MTFs), as previously described (Alford
et al., 2010;Domianet al., 2009; Feinberg et al., 2007, 2012),
to build cardiacmuscle engineeredwith progenitor-derived
and neonatal cardiac myocytes, and assess its structural,
electrophysiological, andcontractileproperties.We isolated
progenitor-derivedmyocytes from a double-reportermouse
ESC line using fluorescence-activated cell sorting (FACS)
(Figure S1 available online), which we previously showed
differentiate into >90% ventricular myocytes based on the
AP morphology revealed by patch-clamp (Domian et al.,
2009). We were able to engineer laminar, anisotropic
myocardium by using micropatterned culture surfaces of
alternating 20-mm-wide lines of fibronectin (FN) and Plur-
onics F-127 (Figure S2A; Domian et al., 2009). For neonate
myocytes, which failed to form tissues in these conditions,
we adopted two alternative approaches. First, we used a
softer Sylgard 527 polydimethylsiloxane (PDMS) (Palche-
sko et al., 2012) to build the same tissue on alternating
20-mm-wide lines of high- and low-density FN (Figure S2B)
for electrophysiological experiments. Second,wedeveloped
an alternative micropattern of FN rectangles organized in a
two-dimensional (2D) pattern similar to a brick wall (Fig-
ure S2C), because the neonate tissues folded the softer
MTFs. With this brick wall micropattern, we were able to
engineer 2D myocardium of neonate myocytes on Sylgard
184 andperformMTF experiments tomeasure contractility.
We quantified the structure of the engineered myocar-
dium using immunofluorescence staining of myofibrils
and gap junctions in the myocytes. Both the progenitor-
and neonate-derived tissues contained large numbers of
myofibrils oriented uniaxially, and the myocytes coupled
via Cx43 gap junctions (Figures 1A and 1F). Neonate-
derived myocardium had well-developed myofibrils with
lateral registration of Z disks between myofibrils both
within myocytes and across transverse cell-cell borders
(Figure 1B). The progenitor-derived myocardium had a
similar network of myofibrils (Figure 1G), but the staining
pattern of the sarcomeric a-actinin suggested an immature
myofibrillar architecture. The neonate-derived myocar-
dium had robust Cx43 staining at the cell-cell junctions
at the myocyte periphery (Figure 1C), consistent with the
Cx43 peripheral localization reported for engineered
myocardium from neonate myocytes (Beauchamp et al.,(M) Cytoskeletal organization as quantified by actin alignment (exam
demonstrated that the progenitor-derived and two types of neona
ANOVA on ranks, p = 0.194).
Scale bars, 25 mm (A and F) and 10 mm (B, C, G, and H). Sample sizes fo
and neonate brick (n = 6). Error bars indicate SD.
Stem Cell R2006; Thomas et al., 2000) and cultured neonatal rat ven-
tricular myocytes (Feinberg et al., 2007). The progenitor-
derived myocardium also exhibited Cx43 at the cell-cell
junctions at the myocyte periphery (Figure 1H); however,
there were fewer visible Cx43 plaques, suggesting a differ-
ence in cell-cell electrical coupling as compared with
neonate-derived tissues.
We quantified the myofibrillar organization of the pro-
genitor- and neonate-derived myocardium to test whether
the different tissue types could be engineered with similar
structural properties. Intensity plots (Figures 1D and 1I) of
the sarcomeric a-actinin staining along myofibrils (yellow
line in Figures 1B and 1G) enabled quantification of the
average Z-disk spacing across tissue types. The contractile
force generated by the sarcomere is length dependent (de
Tombe et al., 2010), but there was no difference between
the Z-disk spacing along the myofibrils, which was 2.01 ±
0.19 mm and 1.99 ± 0.24 mm for progenitor- and neonate-
derived myocardium, respectively (t test, p = 0.227). We
quantified myofibril organization by determining F-actin
orientation at each pixel within the image to create a histo-
gram of orientation angles (Figures 1E and 1J; Bray et al.,
2010; Pong et al., 2011). These data were used to determine
the orientational order parameter (OOP) of each tissue type
as a global metric of myofibril alignment. We structurally
analyzed the progenitor-derived myocardium and both
types of neonate myocardium (the line and brick-wall
micropatterns). The progenitor- and neonate-derived
myocardiumallhad statistically equivalent actin alignment
(Figure 1M; n = 6 per tissue type). We also quantified the
volume of muscle in the engineered tissues by staining
the sarcomeric a-actinin in the Z disks to visualize only
the myocytes. The tissue thickness in the z axis perpendic-
ular to the coverslip ranged from 5 to 7 mm (Figure 1K).
Although the neonate brick-wall myocardium was thinner
by1 mm, all tissues were still only one cell layer thick and
did not multilayer. Approximately 75% of cells in each tis-
sue stained positive for sarcomeric a-actinin, with no statis-
tical difference between tissue types (Figure 1L). These data
suggest that tissues engineered from progenitor-derived
and neonatal ventricular myocytes have a comparable
ability to generate alignedmyofibrils, but a different capac-
ity to generate Cx43 gap junctions.
Electrophysiology of Engineered Myocardium
To analyze the electrophysiological properties of the
myocardium, we conducted optical mapping experimentsple histograms shown in E and J) was analyzed using the OOP, and
te-derived myocardia were statistically equivalent (Kruskal-Wallis
r (K), (L), and (M): progenitor-derived (n = 6), neonate lines (n = 5),
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Figure 2. Electrophysiology of Engineered Myocardium from Neonate Myocytes and Progenitor-Derived Myocytes Shows the
Formation of a Functional Syncytium
(A) Differential interference contrast (DIC) image of engineered neonatal mouse myocardium.
(B) Image of the region highlighted by the dashed yellow box in (A) showing cell-cell borders with the voltage-sensitive fluorescent dye
RH-237.
(C) Example activation map of AP propagation.
(D) Example AP traces (blue, no treatment; green, TTX treatment; red, pacing stimuli) showing conduction block at 10 mM TTX (green X).
(E) Bright-field DIC image of progenitor-derived myocardium.
(F) Image of the region highlighted by the dashed yellow box in (E) showing cell-cell borders with the voltage-sensitive fluorescent dye
RH-237.
(G) Example activation map of AP propagation. Note the later activation times compared with (C).
(H) Example AP traces (blue, no treatment; green, TTX treatment; red, pacing stimuli) show that conduction block does not occur even
at 100 mM TTX, although conduction delay is observed. Also note the slow diastolic depolarization compared with the neonate mouse
tissue in (D).
(I) Longitudinal (L) and transverse (T) CVs are substantially decreased in progenitor-derived myocardium compared with neonate-derived
myocardium (*p < 0.001 and yp = 0.003 for neonate- versus progenitor-derived).
(J) The anisotropy ratio is equivalent between the engineered tissues (p = 0.380).
(K) APD at 50% and 80% repolarization. The progenitor-derived myocardium has a significantly shorter APD80 than the neonate-derived
myocardium (*p = 0.020).
(L) The FRP is significantly shorter in the neonate-derived myocardium than in the progenitor-derived myocardium, indicating post-
repolarization refractoriness and/or slow conduction (*p = 0.004).
Scale bars are 50 mm (A–C and E–G) and 500 ms (D and H). Statistical significance is based on Holm-Sidak multiple pairwise comparisons in
(I) and (K), and Student’s t test in (J) and (L). Sample sizes in (I) and (J): progenitor-derived (n = 7) and neonate (n = 8); (K): progenitor-
derived (n = 8) and neonate (n = 8); and (L): progenitor-derived (n = 5) and neonate (n = 6). Error bars indicate SD.
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an excitation-contraction uncoupler. The neonate- and
progenitor-derived myocardia formed continuous mono-
layers (Figures 2A and 2E, respectively), as indicated by
RH237 staining (Figures 2B and 2F). Bipolar pacing stimuli390 Stem Cell Reports j Vol. 1 j 387–396 j November 19, 2013 j ª2013 Theresulted in activation wavefront propagation in both tissue
types (Figures 2C and 2G). Progenitor-derivedmyocardium
had considerably slower wavefront propagation, as indi-
cated by later activation times (Figures 2G versus 2C),
and significantly decreased longitudinal and transverseAuthors
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Progenitor-Derived versus Neonatal Myocardiumconduction velocities (CVs; Figure 2I). The neonate longi-
tudinal CVs were lower than those previously reported
for patterned neonate strands (Thomas et al., 2000), but
studies in neonatal rat ventricular myocytes have shown
that CVs are higher in myocardial strands than in tissues
(Feinberg et al., 2012). Despite these differences in CV,
the ratio of longitudinal-to-transverse CV (referred to as
the anisotropy ratio) was the same for neonate- and pro-
genitor-derived myocardia (Figure 2J). This suggests a
similar degree of myocyte alignment between tissue types,
in agreement with the actin alignment data (Figure 1M)
and previously reported anisotropy ratios for engineered
myocardium assembled from neonate rat ventricular myo-
cytes (Bursac et al., 2002; Feinberg et al., 2012) and mouse
heart (Gutstein et al., 2001). The AP morphology varied
(Figure 2D and 2H), with the progenitor-derived myocar-
dium exhibiting slow diastolic depolarization between
APs and a shorter mean AP duration (APD) at both 50%
and 80% repolarization (Figure 2K). However, despite
the shorter APD, the progenitor-derived myocardium
had a longer functional refractory period (FRP) than the
neonate-derived myocardium (Figure 2L).
The tissues responded differently to the Na-channel
blocker tetrodotoxin (TTX). Increasing concentrations of
TTX resulted in slowing of conduction in the progenitor-
derived myocardium, as evidenced by longer conduction
delays from the pacing stimulus to local activation
(Figure 2H, blue untreated versus green TTX-treated APs).
Occasional conduction block was observed (green ‘‘X’’ in
Figure 2H, middle panel). However, APs continued to prop-
agate even at the highest concentration of TTX (100 mM) in
all three samples in which TTX was administered. In
contrast, one neonate-derived tissue exhibited complete
conduction block at 1 mM TTX and all samples exhibited
complete or near-complete block (similar to Figure 2D) at
10 mMTTX. This result suggests that the progenitor-derived
myocytes can generate APs without a significant contribu-
tion from Na channels.
Contractility of Engineered Myocardium
We assessed contractility using the MTF assay to quantify
peak systolic stress generated under various pacing condi-
tions. Note that the MTF contractility assay approximates
a single lamellar layer of the ventricular wall and is effec-
tively an isometricmeasurement inwhich the radius of cur-
vature changes as a function of diastolic and systolic stress
(Alford et al., 2010; Feinberg et al., 2007). The PDMS film
thicknesswas calibrated such that theneonate- andprogen-
itor-derived MTFs produced comparable deformations at
peak systole (Figures 3A and 3D). Neonate-derived myocar-
dium had a spontaneous contractile frequency of R1 Hz,
with individual MTFs being captured at pacing frequencies
between 1 and 10 Hz (Figure 3B). All of the neonateStem Cell Rmouse MTFs responded to pacing at 3 and/or 4 Hz,
corresponding to the resting heart rate of neonatal mice
(Hou and Burggren, 1989). In comparison, progenitor-
derived myocardium had a spontaneous contractile fre-
quency, typically <1 Hz, with individual MTFs captured
between 0.5 and 5 Hz (Figure 3E). All of the progenitor-
derived MTFs responded to pacing at 1 and 2 Hz,
corresponding to the embryonic mouse heart rate at
10–11 days of gestation (Gui et al., 1996). Specifically, the
maximum frequency at which most progenitor- and
neonate-derived MTFs could be paced (2 Hz and 4 Hz,
respectively; Figures 3B and 3E) was the same as the FRP.
These results suggest differences in the spontaneous activ-
ity of the myocardial tissues, the excitability of the tissues,
and the maximum contraction rates as a function of
myocyte maturity.
The neonate-derived myocardium generated signifi-
cantly greater peak systolic stresses than the progenitor-
derived myocardium. Example contraction plots for
neonate-derived myocardium (Figure 3C) show that stress
varied with pacing frequency, but was on the order of 5–
10 kPa over a pacing range of 2–8 Hz. Although neonatal
mouse myocardium has been shown to have a positive
force-frequency relationship (Xi et al., 2010), our tissues
derived from neonate myocytes had a negative force-fre-
quency relationship observed from 3–8 Hz pacing (Fig-
ure 3C), consistent with other reports for mouse and rat
engineered heart tissue (de Lange et al., 2011; Feinberg
et al., 2012). In contrast, contraction of the progenitor-
derived tissues (Figure 3F) showed that peak stress was sub-
stantially lower at 1 kPa over a range of 1–3 Hz. The flat
force-frequency relationship for the progenitor-derived
myocardium over the 1–3 Hz pacing range does not
resemble neonatal mouse myocardium or neonate-derived
myocardium, but is consistent with other reports formouse
ESC-derived engineered myocardium (Xi et al., 2010). A
comparison of the peak systolic stress between tissue types
at multiple pacing frequencies illustrates this difference
in contractility (Figure 3G). Peak systolic stress varied
significantly between the neonate- and progenitor-derived
tissues at all pacing frequencies (p < 0.001), but there
was no difference within each tissue type (two-way
ANOVA and the Holm-Sidak method for multiple pairwise
comparisons).DISCUSSION
The current study was motivated by a simple question:
how comparable are our progenitor-derived myocytes to
neonatal myocytes? The differentiation of stem cells into
cardiac myocytes is typically assessed in amanner that pro-
vides little insight into how they function as a tissue, andeports j Vol. 1 j 387–396 j November 19, 2013 j ª2013 The Authors 391
Figure 3. Contractility of Neonate- and Progenitor-Derived
Engineered Myocardia
(A) Representative neonate-derived MTF in diastole (red) and peak
systole (green). Scale bars are 500 mm.
(B) Histogram of the number of neonate-derived MTFs captured as a
function of stimulation frequency.
(C) Example plots of contractile stress generated at various pacing
frequencies in a neonate-derived MTF.
(D) Representative progenitor-derived MTF in diastole (red) and
peak systole (green). Scale bars are 500 mm.
392 Stem Cell Reports j Vol. 1 j 387–396 j November 19, 2013 j ª2013 The
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functionality (Sartiani et al., 2007). Thus, we chose a set of
metrics that define the most important functional charac-
teristic of cardiac myocytes: the ability to self-organize
into and function as laminar myocardium.
Mature ventricular myocytes rebuild their contractile
cytoskeleton and cell-cell junctions continuously. We
assessed the functional implications of the subcellular,
cellular, and multicellular architectures within the engi-
neered tissues to determine whether the electrophysio-
logical and contractile performance of stem cell-derived
myocytes was comparable to that of myocytes isolated
directly from the ventricular myocardium. To perform
this comparison, we evaluated the cellular alignment, gap
junction localization, and cytoskeletal architecture in
engineered tissues. Physiological comparisons of the two
tissues were based on techniques described in previous
studies of engineered tissues (Bursac et al., 2002; Chung
et al., 2011; Feinberg et al., 2012) and classical physiology.
Our findings suggest that immature cardiac myocytes of
stem cell origin may have significant deficits in tissue
genesis as compared with neonates.
As expected, these structural inadequacies were reflected
functionally, in that progenitor-derived tissues had
significantly impaired contractility and electrophysiology
with respect to neonate-derived tissues. These differences
could not be predicted from single-cell measurements, as
cell-cell coupling, gap junction formation, and lateral regis-
tration of myofibrils across cells are emergent properties
of myocardial tissues. The contractility of 3D tissues engi-
neered with human ESC- and iPSC-derivedmyocytes varies
widely, with peak systolic stresses in the range of 0.1–10 kPa
reported in previous studies (Kensah et al., 2013; Tulloch
et al., 2011; Zhang et al., 2013). These studies demonstrated
the ability to engineer human myocardium, but also illus-
trated the difficulty of comparing experiments employing
different cell sources, culture conditions, scaffolds, and
analysis methods. In comparison, the MTF contractility
assay is simple to implement, is reproducible, and has
been demonstrated to work with a wide range of cell types,(E) Histogram of the number of progenitor-derived MTFs captured
as a function of stimulation frequency.
(F) Example plots of contractile stress generated at various pacing
frequencies in a progenitor-derived MTF.
(G) Peak systolic stress as a function of stimulation frequency. The
box plots range from the 25th to 75th percentile, with the median
indicated by the solid line, and whiskers indicate the 10th and 90th
percentiles for pacing frequencies where n R 9 MTFs responded.
There is a statistically significant difference between the neonate-
and progenitor-derived myocardia (two-way ANOVA, p < 0.01). The
sample sizes for each tissue type and pacing frequency are indi-
cated graphically in (B) and (E).
Authors
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2009), neonatal rat ventricular myocytes (Feinberg et al.,
2007, 2012), skeletal muscle (Sun et al., 2013), and vascular
smooth muscle (Alford et al., 2010). Thus, the MTF system
serves as a platform for engineering myocardium with the
same tissue alignment but from different cell sources,
enabling comparable evaluations of the myogenic and
functional potential of these cells in a reproducible system.
Although we made a significant effort to ensure that the
progenitor- and neonate-derived myocardia were as struc-
turally similar as possible, it should be noted that there
are limitations inherent to using these different cell sour-
ces. Specifically, we cannot completely control the hetero-
geneity of the cell population. For both tissue types, the
area of theMTF covered by cardiomyocytes was statistically
equivalent (Figure 1L); however, the 25% remaining cells
were not identified. For neonate-derived myocardium, the
noncardiomyocytes in the primary harvest cells will be a
combination of cardiac fibroblasts, endothelial cells, and
smooth muscle cells. For progenitor-derived myocardium,
the noncardiomyocytes in the FACS population will be a
combination cardiac progenitors that have differentiated
into endothelial cells or smooth muscle cells, or only
partially differentiated into one of these cell types or a
cardiomyocyte (Chien et al., 2008; Domian et al., 2009).
Further, false-positives occur with FACS, so a small percent-
age of these cells may have differentiated into other cell
types. Although we know that noncardiomyocytes cannot
contract on the 1 Hz timescale we measure with the MTFs
because they lack well-formed sarcomeres, we cannot
completely rule out cell-cell coupling or paracrine effects
that might impact the electromechanical function of the
engineered myocardium. Future studies will need to inves-
tigate whether additional FACS, perhaps using a myosin
heavy chain reporter, could further purify the cardiomyo-
cyte population and improve the function of the progeni-
tor-derived myocardium.
Clinically, the laminar ventricular myocardium on the
MTF is similar to the idealized tissue architecture for a ven-
tricular patch for repair of an MI. Researchers have success-
fully used human iPSCs (Nelson et al., 2009) and ESCs
(Kehat et al., 2004) in rodent MI disease models and autol-
ogous mesenchymal stem cells (Katritsis et al., 2005) in
human MI patients, and often have been able to improve
the ejection fraction (contraction). However, these gains
are typically small, often transient, and typically attributed
to paracrine effects that induce angiogenesis rather than to
cell integration with the host myocardium (Passier et al.,
2008). Cell-source selection and the efficacy of the patch
may be improved by an in vitro testing platform that is
easily translated to clinical application. The MTF platform
we used in this study is amenable to thorough in vitro
testing,mechanical conditioning, and (potentially) clinicalStem Cell Rapplications involving a broad range of therapeutic param-
eters (Barron et al., 2003; Radisic et al., 2007).
In conclusion, the observed differences in structure
and function between progenitor-derived myocytes and
neonate myocytes clearly demonstrate the need to estab-
lish metrics for the use of stem cells. A promising method
for performing such quality validation studies is to utilize
traditional histological and physiological assays to evaluate
engineered tissues fabricated from stem cell-derived myo-
cytes. This is important, because as the field moves rapidly
toward applications of stem cells in drug discovery, safety
pharmacology, in vitro disease modeling, and regenerative
medicine, it will be critical for stem cell-derived myocytes
to recapitulate the required performance characteristics.EXPERIMENTAL PROCEDURES
Cardiomyocytes from Mouse ESC Lines and Neonatal
Ventricles
All procedures were approved by the Harvard University Animal
Care and Use Committee. The ESC-derived cardiac progenitor cells
(CPCs) were generated and isolated using previously described
methods (Domian et al., 2009). Briefly, ESC lines were created
from transgenic mice with a combined enhanced GFP (eGFP)
and discosoma species Red (dsRed) reporter system to isolate
CPCs by FACS. The R+G+ CPCs used in these experiments were
previously shown to be highly myogenic and differentiate into
myocytes with a ventricular phenotype (process illustrated in Fig-
ure S1). CPCs were cultured on coverslips with micropatterned FN
lines for 3–5 days to differentiate the cells into cardiac myocytes.
They were then trypsinized, resuspended, and seeded onto micro-
patterned coverslips for 2 days prior to immunohistochemistry
and electrophysiological assays, or onMTFs for contractility assays.
Neonate myocytes were isolated from 2-day-old neonatal C57/Bl6
mice via a procedure adapted from previously published methods
for isolating neonatal rat ventricular myocytes (Alford et al., 2010;
Feinberg et al., 2007). Ventricles were extracted, enzymatically
dissociated, and resuspended in culture. Myocytes were cultured
for 4 days on micropatterned coverslips prior to immunohisto-
chemistry and electrophysiological assays, or onMTFs for contrac-
tility assays.Engineered Myocardium
The method for engineering the myocardium was adapted from
previously published methods (Alford et al., 2010; Domian et al.,
2009; Feinberg et al., 2007) and optimized for each cell type and
analysis. For progenitor-derived myocytes, coverslips were spin-
coated with Sylgard 184 PDMS (Dow Corning). For neonate myo-
cytes, coverslips were spin-coated with either Sylgard 184 PDMS or
Sylgard 527 PDMS. The PDMS-coated coverslipsweremicrocontact
printed (mCP) with FN using one of three patterns (anisotropic,
lines, or bricks; Figure S2). The anisotropic and line patterns
consisted of 20-mm-wide, 20-mm-spaced FN lines and backfilled
with 1% Pluronics F-127 for progenitor-derived myocytes (Fig-
ure S2A) or low-density FN for neonate myocytes on Sylgard 527eports j Vol. 1 j 387–396 j November 19, 2013 j ª2013 The Authors 393
Stem Cell Reports
Progenitor-Derived versus Neonatal Myocardium(Figure S2B). The brick patten consisted of 20-mm-wide, 100-mm-
long FN rectangles spaced 3 mm apart and backfilled with 1% Plur-
onics F-127 (Figure S2C). The MTFs were fabricated according to
published methods using Sylgard 184 (Feinberg et al., 2007) and
then patterned with FN lines for the progenitor-derived myocytes
or FN bricks for the neonate myocytes.
MTF Contractility Assay
MTF contractility assays were performed and analyzed according
to previously publishedmethods (Alford et al., 2010). Contractility
assays were conducted using a custom-built organ bath system
with a Petri dish mounted in an aluminum stage plate with inte-
grated resistive heaters that maintained the Tyrode’s solution
at 36C ± 1C. MTF contractions were initiated using parallel
platinum wire electrodes to apply field stimulation (Myopacer;
IonOptix) consisting of 7–14 V, 10-ms-duration square wave at
pacing rates of 1–10 Hz.
Optical Mapping Experiments
Optical recordings of the transmembrane potential (Vm) in the
engineered myocardium were performed on days concurrent
with the contractility assays. Measurements were carried out in
normal Tyrode’s solution at 35C using the voltage-sensitive dye
RH237 (Invitrogen) and the excitation-contraction uncoupler
Blebbistatin (Calbiochem). To block sodium ion channels, TTX
(Sigma) was added at working concentrations of 1, 10, and
100 mM. Fluorescence recordings were obtained using an inverted
microscope (Zeiss Axiovert 200) with a 403 objective (Zeiss EC
Plan-Neofluar, numerical aperture 1.3). Pacing was applied via
bipolar point stimulation from the tips of two platinum wires
located 1 mm above the monolayer. Pacing frequency was
increased in steps of 0.5 Hz, and the highest frequencymaintained
was deemed the FRP. CV vector fields were calculated from interpo-
lated activation maps (Bayly et al., 1998). The APD was calculated
at 50% and 80% repolarization from digitized voltage signals low-
pass filtered to improve the signal-to-noise ratio.
Quantitative Immunofluorescence of Cytoskeletal
Structure
The engineered myocardium on the PDMS-coated coverslips was
fixed and stained at time points concurrent with MTF and optical
mapping using a modification of previously published methods
(Alford et al., 2010; Feinberg et al., 2007). The Z disks in the
sarcomeres were stained with mouse anti-(sarcomeric a-actinin)
primary antibody (Sigma) and gap junctions were stained with
rabbit anti-Cx43 primary antibody (Sigma). Samples were then
concurrently stained with Alexa Fluor 488 goat anti-rabbit and
Alexa Fluor 546 goat anti-mouse secondary antibodies, Alexa
Fluor 633 phalloidin and 40,6-diamidino-2-phenylindol (Invitro-
gen), mounted on microscope slides and imaged with a Zeiss
LSM 5 Live laser scanning confocal microscope. Sarcomere
spacing along myofibrils was determined from the sarcomeric
a-actinin staining using ImageJ (NIH). The thickness and percent
area of the engineered myocardium were determined from z
stacks of a-actinin using ImageJ to create binary images and
custom MATLAB code for quantification. Actin alignment was
quantified based on published methods (Bray et al., 2010) and394 Stem Cell Reports j Vol. 1 j 387–396 j November 19, 2013 j ª2013 Thereported as the 2D orientation order parameter (OOP) (Hamley,
2007).
Statistical Analysis
Statistical analysis for two groups that passed the normality test
was conducted using Student’s t test, or otherwise with the
Mann-Whitney rank sum test. Statistical analysis of more than
two groupswas conducted using one- or two-wayANOVA followed
by multiple pairwise comparison using the Holm-Sidak method.
All data were plotted and statistically analyzed using SigmaPlot
(Systat Software), with significant difference based on p < 0.05.
SUPPLEMENTAL INFORMATION
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